Rentschler Biopharma SE, a contract development and manufacturing organization (CDMO) for biopharmaceuticals, including advanced therapy medicinal products (ATMPs), appointed Günter Stempfer site head of the company’s facility in Laupheim, Germany.  He will report to chief operating officer Christiane Bardroff.

In his new role, Stempfer will head the site leadership team in Laupheim and will be part of the global leadership team. Stempfer is responsible for continuously identifying opportunities for improvement, reliably ensuring the development and production of complex biopharmaceuticals for clients, and implementing innovative changes at the site in coordination with the extended executive team.

Stempfer joined Rentschler Biopharma in 2022 as head of global strategic development. Prior to that, he advised the company in the area of production and led daily operations at the Laupheim site in close collaboration with the company leadership team since the summer of 2021.

Stempfer brings more than 25 years of experience in the biopharmaceutical industry. He has held various leadership positions, including site head at Sandoz in Kundl, Austria; project director at Novartis in Huningue, France; and director Global techops at Polpharma in Poland.

Christiane Bardroff said, “The appointment of Günter Stempfer as Site Head for Laupheim is an optimal solution. He has a deep knowledge of this production site and a proven track record of working effectively and successfully with the local team. With Günter Stempfer’s strong leadership and exceptional capabilities, we will ensure operational excellence at our headquarter’s site, in the interest of sustainability and patient care.”

“Throughout my various roles at Rentschler Biopharma, my primary objective has always remained the same: the efficient, accurate, and timely delivery, also for complex development and production tasks, to enable our clients to provide effective medicines for seriously ill patients,” said Stempfer. “The highly competent team in Laupheim shares this same commitment, and I look forward to our continued collaboration. At the same time, I will utilize my strong ties to our Stevenage and Milford sites to further strengthen collaboration and exchange across sites.”